Pancreatic cancer |
Up-regulated |
Oncogenic |
Cell proliferation, apoptosis, migration, invasive, progression, Warburg effect, cell cycle control |
HIF-1α, VEGF, miR-142, EGFR, AKT, p-AKT, miR-107, miR-133a, FEZF1 |
[20,21] |
Ovarian cancer |
Up-regulated |
Oncogenic |
Cell proliferation, apoptosis |
STAT3, p-STAT3 |
[23] |
Nasopharyngeal carcinoma |
Up-regulated |
Oncogenic |
Cell proliferation, migration, invasive, cell cycle control, EMT |
P21, CyclinD1, E-cadherin, Vimentin, N-cadherin, Wnt/β-catenin |
[25] |
Hepatocellular carcinoma |
Up-regulated |
Oncogenic |
Cell proliferation, migration, invasive, cell cycle control, EMT |
JAK/STAT3, E-cadherin, N-cadherin, Vimentin |
[28] |
Cervical cancer |
Up-regulated |
Oncogenic |
No description |
No description |
[32,33] |
Colorectal cancer |
Up-regulated |
Oncogenic |
Cell proliferation, apoptosis, migration, invasive, progression, Warburg effect, cell cycle control |
PKM2, STAT3, FEZF1MCL1, BIRC5, CCND1, BCL2L1, CDH1, MMP2, MMP9 |
[16,35] |
Multiple myeloma |
Up-regulated |
Oncogenic |
Cell proliferation, cell cycle control, apoptosis |
miR-610, AKT3 |
[37] |
Breast cancer |
Up-regulated |
Oncogenic |
Cell proliferation, migration, invasive, progression |
miR-30a, Nanog, Oct4, SOX2 |
[39] |
Osteosarcoma |
Up-regulated |
Oncogenic |
Cell proliferation, migration, invasive, progression |
miR-4443, NUPR1 |
[41] |
Non-small-cell lung cancer |
Up-regulated |
Oncogenic |
Cell proliferation, migration, invasive, progression, EMT cell cycle control |
CDK2, CDK4, CDK6, cleaved-caspase3, total-caspase3, cleaved-caspase9, total-caspase9, cleaved-PARP, P57, LSD1, EZH2, Slug, total-PARP, Vimentin, HUR, FEZF1, ZO-1, Snail, Twist, AXIN1, E-cadherin, β-catenin TCF4 |
[44–47] |
Gastric cancer |
Up-regulated |
Oncogenic |
Cell proliferation, apoptosis, progression, cell cycle control |
Wnt/β-catenin, p21, CDK2, CDK4, CDK6, LSD1, CyclinD1, SP1, E-cadherin, H3K4me3 |
[49–51] |